Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Completed 3

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

CNS 3Sarcoma 2Thoracic 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Melanoma 86Carcinoma, Renal Cell 29Lymphoma 26Kidney Neoplasms 26Leukemia 25Leukemia, Myeloid, Acute 24Lymphoma, Follicular 16Lymphoma, Non-Hodgkin 15Lymphoma, Mantle-Cell 14Precursor Cell Lymphoblastic Leukemia-Lymphoma 13Leukemia, Lymphocytic, Chronic, B-Cell 13Breast Neoplasms 12Neoplasm Metastasis 11Lymphoma, Large B-Cell, Diffuse 10Lymphoma, B-Cell, Marginal Zone 10Skin Neoplasms 9Myelodysplastic Syndromes 9Lymphoma, Large-Cell, Immunoblastic 9Hodgkin Disease 9Burkitt Lymphoma 9Neuroblastoma 8Congenital Abnormalities 8Recurrence 7Ovarian Neoplasms 7Multiple Myeloma 7Carcinoma, Non-Small-Cell Lung 7Pancreatic Neoplasms 6Leukemia, Myelomonocytic, Chronic 6Gliosarcoma 6Glioblastoma 6

Interventions

Hydroxyurea 4aldesleukin 3Magnetic Resonance Spectroscopy 3Imatinib Mesylate 3Everolimus 3Temozolomide 2Surveys and Questionnaires 2Surgical Procedures, Operative 2Radiotherapy, Intensity-Modulated 2Radiotherapy, Conformal 2Psychiatric Rehabilitation 2Proton Therapy 2Paclitaxel 2Laser Speckle Contrast Imaging 2Filgrastim 2Donepezil 2Cyclophosphamide 2Carmustine 2Bortezomib 2Bevacizumab 2Aminolevulinic Acid 290Y-octreotide, DOTA-Tyr(3)- 2vistusertib 1vatalanib 1trametinib 1tozuleristide 1temsirolimus 1sonidegib 1sargramostim 1ribociclib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × Meningioma × aldesleukin × Clear all
NCT01967823 2021-03-24

T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
11 enrolled 12 charts
BreastCNSDermatologicGastrointestinalThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Liver Neoplasms, Melanoma, Meningioma, Neoplasm Metastasis

NCT01082926 2015-06-08

Phase I Study of Cellular Immunotherapy for Recurrent/Refractory Malignant Glioma Using Intratumoral Infusions of GRm13Z40-2, An Allogeneic CD8+ Cytolitic T-Cell Line Genetically Modified to Express the IL 13-Zetakine and HyTK and to be Resistant to Glucocorticoids, in Combination With Interleukin-2

City of Hope Medical Center

Phase 1 Completed
6 enrolled
CNSSarcoma

Astrocytoma, Brain Neoplasms, Ependymoma, Glioblastoma, Glioma, Meningioma, Oligodendroglioma, Neuroectodermal Tumors, Primitive, Gliosarcoma

NCT00014573 2013-04-08

Chemotherapy and Vaccine Therapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation and Interleukin-2 in Treating Patients With Recurrent or Refractory Brain Cancer

Barbara Ann Karmanos Cancer Institute

Phase 2 Completed
CNSSarcoma

Familial ependymoma, Astrocytoma, Brain Neoplasms, Ependymoma, Glioblastoma, Glioma, Medulloblastoma, Meningioma, Central Nervous System Neoplasms, Choroid Plexus Neoplasms, Neuroectodermal Tumors, Primitive, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡